As Chair of the meeting, Ruth Plummer, MD, of Newcastle University, Newcastle, UK, give us her overview of the highlights…
Browsing: General
At the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK, Anita Hill, MBChB (Hons), MRCP,…
Thrombosis is the leading cause of morbidity and mortality in paroxysmal nocturnal hemoglobinuria (PNH). In this interview, Anita Hill, MBChB…
The Systemic Anti-Cancer Therapy (SACT) Competency Passport, produced by leading cancer nuses in partnership with the UK Oncology Nursing Society…
How to maintain optimal patient safety and wellbeing is a constant concern and priority for healthcare professionals. At the UK…
Gerry Hanna, MD, from Queens University Belfast, Belfast, UK, provides an insight into the two new landmark platforms investigating radiotherapy-drug…
CT scans are currently the standard for mapping targeted areas for cancer treatment; however, MRI has been shown to produce…
With the increasing life expectancy of cancer patients, the long-term consequences of cancer therapy are becoming an increasing issue. Anthracycline-induced…
Here, Jacob Kettle, PharmD, BCOP, of the University of Missouri Health Care, Columbia, MO, shares his perspective on the different…
Jacob Kettle, PharmD, BCOP, of the University of Missouri Health Care, Columbia, MO, discusses the different ways in which pharmacists…
In this interview, Christopher Campen, PharmD, BCOP, from the GHS Cancer Institute, Greenville, SC, discusses combining immune checkpoint inhibitors for…
The unique side effects that accompany the use of immune checkpoint inhibitors for the treatment of cancer need to be…
Patient-reported outcomes (PROs) give a greater insight into the lives of patients and their perspectives on the treatment received. Here,…
The expression of programmed death-ligand 1 (PD-L1) can be used as a clinical biomarker to determine the efficacy of immune…
Immune checkpoint inhibitors are effective in the management of various cancers. However, there are a number of side effects that…
Emily L. Harris, Ph.D., M.P.H.,National Cancer Institute – Deputy Associate Director, explains ARA Process for Large Budget Grants Program director…
Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks Cancer Care for Pediatctrics and Young Adults Rare diseases in…
Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks about Variety of Developments in Cancer Genomics Translate discoveries in…
Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, FDA Approval of Pembrolizumab The 1st approval of a drug that is…
How Do Thoracic Surgeons Assess Fitness for Surgery
Dr. David Harpole, Duke University Medical Center, describes the mediastinoscopy and its use in lung cancer staging.
Dr. David Harpole, Duke University Medical Center, describes the sleeve resection and how it can help selected patients with large…
Dr. David Harpole, Duke University Medical Center, defines the concept of mediastinal node sterilization and its use after neoadjuvant therapy.
Dr. David Harpole, Duke University Medical Center, compares traditional open thoracotomy with video-assisted thorascopic surgery, highlighting the advantages of the…
How Rate of Progression Can Affect Treatment Decisions
Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.
Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.
Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.
Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.
Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and…
Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment…
Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first…
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology
Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.
Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in…
2nd video in GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and…
4th video in GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and…
Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses using adjuvant chemotherapy for elderly and frail patients. What was seen in…
On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung…
GRACE is happy to present the 9th and final video in our series ASCO 2016 Lung Cancer Roundtable, Highlights and…
Jose F. Leis, MD, PhD, explains how Control of disease can be achieved with Ibrutnib High-risk Relapsed Refractory patients will…
Richard R. Furman, MD, talks about how MBL Patients Don’t Need Bone Marrow Biopsies MBL can be followed by CBCs…
Jose F. Leis, MD, PhD, explains Venetoclax Rapidly Moving as Best 2nd-line Therapy SCT still remains as the only curative…
Matthew S. Davids, MD, MMSc, talks about how Venetoclax w Rituximab progressed the furthest Phase 3 Data shows the combination…
Richard R. Furman, MD, talks about how MBL Patients Don’t Need Bone Marrow Biopsies MBL can be followed by CBCs…
Jose F. Leis, MD, PhD, explains PET-Scans Not as Specific for Richter’s Transformation Biopsies are essential for those who fail…
Amer M Zeidan, MBBS, talks about A lot of Questions on the Best Use of New Drugs Still waiting on…
Matthew S. Davids, MD, MMSc, explains Role of Chimeric Antigen Receptor T Cells CAR-T Cell after multiple novel agent-based therapies…
Richard M. Stone, MD, talks about Incorporating Midostaurin for FLT3 Positive Patients Use Gemtuzumab Ozogamicin for CD33 Expression at Imedex…
GRACE is happy to present the 7th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in…